| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
4-Pyridoxic acid-d3 does not have a specific pharmacological target as it is a stable isotope-labeled metabolite used as an analytical standard. 4-Pyridoxic acid is the primary catabolic product of vitamin B6 (pyridoxine) and is excreted in urine. Its "target" in research is as a biomarker for vitamin B6 status and metabolism. The deuterated form is used as an internal standard in analytical chemistry for the accurate quantification of 4-pyridoxic acid and other vitamin B6 metabolites in biological samples.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro activity of 4-Pyridoxic acid-d3 is not evaluated as a bioactive compound. Its utility lies in its role as an internal standard for mass spectrometry-based quantification of vitamin B6 metabolites. It is used in analytical method development to accurately measure vitamin B6 status in biological samples. Its "activity" is reflected in its performance as an analytical standard, providing accurate and precise quantification of 4-pyridoxic acid in research and clinical diagnostics. |
| ln Vivo |
In vivo, 4-Pyridoxic acid-d3 is not administered as a therapeutic agent. It is used as an internal standard in research studies to quantify 4-pyridoxic acid and other vitamin B6 metabolites in biological samples such as urine and plasma. These studies assess vitamin B6 status and metabolism in human populations and its association with health outcomes. The deuterated compound ensures accurate measurement by compensating for matrix effects and variations in sample preparation.
|
| Enzyme Assay |
In vitro enzyme assays with 4-Pyridoxic acid-d3 typically involve using the compound as an internal standard in assays that measure the activity of enzymes involved in vitamin B6 metabolism, such as pyridoxal kinase or pyridoxine 5'-phosphate oxidase. The deuterated standard is added to samples to control for extraction efficiency and ionization suppression in mass spectrometry analysis. Standard protocols involve spiking samples with a known amount of the deuterated standard, processing the samples, and analyzing by LC-MS/MS.
|
| Cell Assay |
4-Pyridoxic acid-d3 is not typically used in cell culture experiments as a bioactive compound. However, it may be employed as an internal standard in cell-based studies investigating vitamin B6 metabolism. Cells are treated with vitamin B6 or its derivatives, and the deuterated standard is used to quantify 4-pyridoxic acid and other metabolites in cell lysates or culture media by LC-MS/MS. Its role is strictly analytical rather than biological.
|
| Animal Protocol |
In vivo animal experiments with 4-Pyridoxic acid-d3 typically involve using the compound as an internal standard in pharmacokinetic or metabolic studies of vitamin B6. Animals are administered vitamin B6 or pyridoxine, and blood, urine, and tissue samples are collected. The deuterated standard is added to samples to quantify vitamin B6 metabolites by LC-MS/MS. These studies provide data on the absorption, distribution, metabolism, and excretion of vitamin B6.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of 4-Pyridoxic acid-d3 are relevant to its use as an internal standard. The deuterated compound has essentially identical physicochemical properties to the unlabeled 4-pyridoxic acid, making it an ideal internal standard for PK studies of vitamin B6 metabolism. It co-elutes with the analyte during chromatography and has similar ionization efficiency in mass spectrometry, allowing for accurate quantification. It is not a drug and its PK properties are studied only in the context of analytical method development.
|
| Toxicity/Toxicokinetics |
4-Pyridoxic acid-d3 has a low toxicity profile consistent with its use as an analytical standard. 4-Pyridoxic acid is a normal catabolic product of vitamin B6 and is present in the body as a natural metabolite. The deuterium label does not introduce additional toxicity. Standard laboratory safety practices are sufficient for handling. It is not classified as a hazardous substance and is used in research applications including medical, environmental, and industrial research.
|
| References | |
| Additional Infomation |
4-Pyridoxic acid-d3 is a deuterated form of 4-Pyridoxic acid, which is a metabolite of vitamin B6. It is a stable isotope-labeled compound used in various scientific research fields, including medical, environmental, and industrial research. It serves as an internal standard for the accurate quantification of vitamin B6 metabolites in biological samples. The compound is not a drug and has no therapeutic indications. It is available for laboratory research use only as an analytical standard.
|
| Molecular Formula |
C8H9NO4
|
|---|---|
| Molecular Weight |
186.179847478867
|
| Exact Mass |
186.071
|
| CAS # |
1435934-03-4
|
| Related CAS # |
4-Pyridoxic acid;82-82-6
|
| PubChem CID |
117064439
|
| Appearance |
Light yellow to light brown solid powder
|
| LogP |
0.1
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
13
|
| Complexity |
197
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])C1=NC=C(C(=C1O)C(=O)O)CO
|
| InChi Key |
HXACOUQIXZGNBF-FIBGUPNXSA-N
|
| InChi Code |
InChI=1S/C8H9NO4/c1-4-7(11)6(8(12)13)5(3-10)2-9-4/h2,10-11H,3H2,1H3,(H,12,13)/i1D3
|
| Chemical Name |
3-hydroxy-5-(hydroxymethyl)-2-(trideuteriomethyl)pyridine-4-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.3711 mL | 26.8557 mL | 53.7115 mL | |
| 5 mM | 1.0742 mL | 5.3711 mL | 10.7423 mL | |
| 10 mM | 0.5371 mL | 2.6856 mL | 5.3711 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
